|
Volumn 62, Issue 1, 2002, Pages 245-252
|
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
a,b,c,d a,b,c a,b,c,d d d d d d d d d d d d d d d d d d more.. |
Author keywords
Cardiovascular calcification; End stage renal disease; Hypercalcemia; Mineral metabolism; Randomized clinical trial
|
Indexed keywords
ALUMINUM;
CALCITRIOL;
CALCIUM;
CALCIUM ACETATE;
CALCIUM CARBONATE;
CALCIUM PHOSPHATE;
PARATHYROID HORMONE;
PHOSPHATE BINDING AGENT;
PHOSPHORUS;
POLYMER;
SERTUERNER;
SEVELAMER;
ADULT;
AGED;
AORTA;
ARTERY CALCIFICATION;
ARTICLE;
CALCIUM BLOOD LEVEL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY;
DISEASE COURSE;
DRUG SAFETY;
DRUG TOLERABILITY;
ELECTRON BEAM TOMOGRAPHY;
FEMALE;
HEMODIALYSIS PATIENT;
HUMAN;
HYPERCALCEMIA;
MAJOR CLINICAL STUDY;
MALE;
PARATHYROID HORMONE BLOOD LEVEL;
PHOSPHATE BLOOD LEVEL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
|
EID: 0036310682
PISSN: 00852538
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1523-1755.2002.00434.x Document Type: Article |
Times cited : (1362)
|
References (38)
|